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Myelodysplastic syndromes represent a group of heterogeneous hematopoietic neoplasms
derived from an abnormal multipotent progenitor cell, characterized by a hyperproliferative
bone marrow, dysplasia of the cellular hemopoietic elements and ineffective erythropoiesis.
Anemia is a common ﬁnding in myelodysplastic syndrome patients, and blood transfusions
are  the only therapeutic option in approximately 40% of cases. The most serious side effect
of  regular blood transfusion is iron overload.
Currently, cardiovascular magnetic resonance using T2 is routinely used to identify
patients with myocardial iron overload and to guide chelation therapy, tailored to prevent
iron  toxicity in the heart. This is a major validated non-invasive measure of myocardial
iron overloading and is superior to surrogates such as serum ferritin, liver iron, ventricular
ejection fraction and tissue Doppler parameters.
The indication for iron chelation therapy in myelodysplastic syndrome patients is cur-
rently  controversial. However, cardiovascular magnetic resonance may offer an excellent
non-invasive, diagnostic tool for iron overload assessment in myelodysplastic syndromes.
Further studies are needed to establish the precise indications of chelation therapy and the
clinical implications of this treatment on survival in myelodysplastic syndromes.©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.IntroductionMyelodysplastic syndrome (MDS) comprises an acquired
primitive stem cell disorder resulting in ineffective
hematopoiesis manifested by variable degrees and numbers
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reserved.of cytopenias, as well as an increased risk of transformation
to acute leukemia. MDS is relatively common with a reported
incidence of 3.5–4.9 per 100,000 people.1 The incidenceery Center, 356 Syggrou Ave., GR-17674, Athens, Greece.
increases to 28–36 per 100,000 in over 80-year-old individuals,
making it as common as myeloma in this age group.2 Red
blood cell (RBC) transfusions comprise the most effective
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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reatment of anemia in MDS  patients, in the expense of organ
amaging iron overload.
Magnetic resonance imaging (MRI) has been successfully
sed for the evaluation of myocardial and liver iron overload.
RI  is the only technique able to provide non-invasive infor-
ation about iron overload, as well as microcirculation defects
nd the detection of myocardial scars.
yelodysplastic  syndromes
DS  represent a group of heterogeneous hematopoietic dis-
rders derived from an abnormal multipotent progenitor cell,
haracterized by a hyperproliferative bone marrow, dyspla-
ia of the cellular hemopoietic elements, and ineffective
ematopoiesis (Figure 1). Peripheral blood cytopenias and
arked morphologic dysplasias are prominent and ineffec-
ive erythropoiesis results in symptomatic anemia.3 Cellular
ysfunction results in an increased risk of infection, bleeding
endency due to thrombocytopenia, and need for transfusions
n most MDS  patients.4 MDS  can be classiﬁed as primary
idiopathic) or secondary (therapy-related), the latter being
ssociated with prior radiotherapy, chemotherapeutic agents,
nd immunosuppression therapy.5 Other risk factors for MDS
evelopment include benzene exposure, occupational chemi-
als, tobacco exposure, excessive alcohol, viral infections, and
utoimmune disorders, as well as chronic inﬂammation.5 A
seful classiﬁcation of MDS  according to their pathogenesis,
ytological features and speciﬁc karyotypes, was proposed
nitially by the French-American-British (FAB) Cooperative
tudy Group.6 More  recently, the World Health Organization
WHO) worked out an updated classiﬁcation that represents
n extension of the FAB proposal, with several modiﬁcations.7
lterations in many  individual biological pathways have
een implicated in MDS  pathophysiology. However, the pri-
ary  hypothesis involves an initial deleterious genetic event
ithin a hematopoietic stem cell, subsequent development
f excessive cytokines/inﬂammatory response leading to
 proapoptotic/proliferative state, resulting in peripheral
ytopenias despite a hypercellular bone marrow. Furthermore,
igure 1 – Characteristic bone marrow ﬁlms in myelodysplastic s
gray arrow). (B) Dysplastic megakaryocyte with multiple separat
mages courtesy of Dr V. Karali (First Department of Propaedeutic
thens, Greece). 1 5;3  7(4):252–258 253
the presence of detectable cytogenetic abnormalities in
approximately 40–70% of patients with primary MDS  and over
80% with secondary MDS, as well as the validated prognostic
value of speciﬁc cytogenetic aberrations in MDS,  supports the
theory of an incidental genetic event.8
Anemia,  transfusion  and  iron  overload  in
myelodysplastic  syndrome  patients
A limited number of effective treatment options are avail-
able to treat anemia and thus help to prevent iron overload
and other transfusion-related side effects in MDS  patients.
A direct approach is to correct anemia by administering
hematopoietic growth factors, i.e. erythropoietin with or with-
out granulocyte-colony stimulating factor (G-CSF).9 Other
drugs, such as lenalidomide, cyclosporine-A and antithymo-
cyte globulin act in certain subgroups of MDS  patients and may
improve or correct anemia.10–12 Allogeneic stem cell trans-
plantation is the only curative approach.13
RBC transfusions are considered in MDS  patients when
hemoglobin (Hb) <8 g/dL, and may provide temporary relief
from the symptoms of anemia, but they also add extra iron
to the body.14 And while there are therapies, as mentioned
above, that can restore the production of RBC so that patients
can become transfusion independent, they are not effective
in all MDS  patients. In fact, for approximately 40% of MDS
patients, transfusions are the only option to treat the symp-
toms of anemia.4
Supportive therapy with regular RBC transfusions can lead
to elevated levels of iron in the blood and other tissues.
The actual prevalence of iron overload in transfused MDS
patients has not been systematically documented.15 Each unit
of packed RBC contains about 250 mg  of iron. As a general rule,
iron overload occurs after the transfusion of 20 units of RBC.15
Thus, MDS patients who receive transfusions for their anemia
are at risk for iron overload. In addition to iron overload as a
result of multiple transfusions, MDS patients with sideroblas-
tic anemia may develop iron overload subsequent to excessive
absorption of iron from food.16
yndrome. (A) Giant granulocyte (black arrow) and blast cell
ed nuclei (black arrow) and pseudo-Pelger cells (gray arrow).
 and Internal Medicine, Athens University Medical School,
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MDS  patients considered to be eligible for iron chela-
tion therapy are transplant recipient candidates. In recent
years, different studies highlighted iron overload as a neg-
ative prognostic indicator in patients undergoing stem cell
transplantation. In a cohort of 590 patients who underwent
myeloablative stem cell transplantation, Armand et al. found
a strong negative association between high serum ferritin lev-
els and overall and disease-free survival. This association was
seen in patients affected either by acute myeloid leukemia or
MDS.17
Iron  overload  and  survival  in  myelodysplastic
syndrome
Transfusion dependency is associated with shortened over-
all survival and leukemia-free survival in MDS; however, it is
not clear whether this effect is mediated by transfusional iron
overload itself or if need for RBC transfusion is a marker of
disease severity.18 The contribution of anemia itself to cardiac
dysfunction in a predominantly older patient population as
well as lack of consideration in the International Prognostic
Scoring System (IPSS) of the severity of anemia are confound-
ing factors that make this evaluation difﬁcult. Furthermore,
worsening of survival with increasing serum ferritin values
has been observed in patients with refractory anemia, refrac-
tory anemia with ringed sideroblasts, and 5q-types of MDS,
but not in patients with refractory cytopenia and multilin-
eage dysplasia, suggesting that the longevity or other factors
in patients with the aforementioned subtypes make them sus-
ceptible to the adverse effects of iron overload.19 However,
it must be noted that all this evidence is indirect and large
prospective studies that correlate accurate markers of iron
overload, such MRI  measurements of tissue iron and non-
transferrin-bound iron (NTBI)/labile plasma iron (LPI) with
survival are necessary to conclusively determine the impact
of iron overload on survival in MDS.
In addition to negatively impacting prognosis, anemia
and transfusion dependence have signiﬁcant impact on the
quality of life of MDS  patients. Despite the effects of ane-
mia  and transfusion dependence on disease outcomes and
patient quality of life, the clinical impact of iron overload
in MDS  patients remains controversial.20 Studies of hered-
itary hemoglobinopathies (e.g. -thalassemia) have shown
causation for iron overload and organ toxicities.21 Clinical con-
sequences of transfusion iron overload in non-thalassemic
adults have been previously reported by Schafer et al.22
These authors also reported that long-term deferoxamine
iron chelation therapy was effective not only in retarding but
even reversing organ damage caused by parenchymal iron
overload.23 However, evidence linking organ iron accumula-
tion with morbidity in MDS  is indirect. In a study of refractory
anemia with ringed sideroblasts, it was found that mild iron
overload was common at presentation, but clinical manifes-
tations occurred only in patients who  had a regular need for
RBC transfusions. Complications of iron overload were the
24most common causes of death. More  recently, the effect
of transfusion dependence and secondary iron overload on
survival of MDS  patients, classiﬁed according to the World
Health Organization (WHO) criteria, were also studied. Overall, 2 0 1 5;3  7(4):252–258
transfusion dependence was found to signiﬁcantly worsen the
probability of survival and to increase the risk of progres-
sion to leukemia in MDS  patients. An inverse relationship was
observed between transfusions requirement and probability of
survival. The negative impact of transfusion dependency was
more pronounced in patients with refractory anemia, refrac-
tory anemia with ringed sideroblasts and MDS  with isolated
deletion 5q. Overall, the most common non-leukemic cause
of death was heart failure. Transfusional iron overload, as
assessed by serum ferritin, was associated with worse sur-
vival in patients receiving regular RBC transfusions. The effect
of iron overload was mainly noticeable among patients with
refractory anemia, who have a median survival of more  than
ﬁve years and are more  prone to develop long-term toxicity of
iron overload.25 These observations indicate that the develop-
ment of secondary iron overload per se worsens the survival of
subgroups of transfusion dependent patients with MDS.  Find-
ings of a retrospective, single institution study suggest that
iron overload signiﬁcantly contributes to treatment related
mortality in MDS. Finally, iron overload in MDS  patients under-
going allogeneic stem cell transplantation may be associated
with adverse outcomes.26
Small studies using cardiovascular magnetic resonance
(CMR) techniques have shown variable and infrequent inci-
dence of cardiac iron accumulation. Regardless of organ
damage, iron overload may increase risk of infection by sup-
plying readily available iron to support microorganism growth,
while several retrospective studies have suggested that trans-
fusion dependence inﬂuences subsequent overall survival and
evolution to leukemia.27 Additional prospective trials using
accurate iron overload markers are required to conclusively
determine the impact of iron overload on overall survival in
patients with MDS.
Management  of  transfusion-related  iron
overload  in  myelodysplastic  syndrome  patients
Iron overload therapeutic options can decrease transfusion
needs as well as improve quality of life in MDS  patients.
Attainment of transfusion independence in the absence of
cytogenetic responses with disease-modifying agents has
been associated with improved overall survival.28 Patients
who receive hypomethylating agents have demonstrated
improvements in quality of life measures. Iron overload
remains a risk for patients who have continued transfusion
dependence even with hypomethylating therapy; therefore,
iron chelation therapy may be recommended.29
By consensus, the following groups of MDS  patients should
be regarded as candidates for iron chelating therapy:
(i) Patients with frank iron overload (e.g. stable/increasing
serum ferritin >1000 ng/mL without signs of inﬂamma-
tion or liver disease), who are transfusion dependent (at
any frequency) and have a life expectancy of at least one
year.
(ii) Transfusion dependent patients, who receive >2 RBC con-
centrates per month, at any ferritin level, and have a life
expectancy of more  than two years (exception: patients
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with frank iron deﬁciency, e.g. chronic gastrointestinal
tract bleeding).
iii) In selected cases, iron chelating therapy can also be con-
sidered when life expectancy is less than two years.
Examples are planned curative therapy (stem cell trans-
plantation), massive iron overload with consecutive
organopathy, or massive iron overload, judged to signif-
icantly reduce the quality of life. Additional parameters
that may inﬂuence the decision to treat individual MDS
patients with iron chelating agents are age (geriatric
aspects), social and mental features, and comorbidity
(organopathy).30
ardiac  iron  in  myelodysplastic  syndromes
he organ damage of most concern, given the advanced age
nd comorbidities in many  MDS  patients is cardiac dysfunc-
ion resulting from myocardial iron deposition. Cardiac iron
as been observed at autopsy in patients who have died
f acute leukemia or other transfusion dependent anemias
nd correlates with the number of RBC transfusions; how-
ver these data are confounded by the contribution of anemia
tself to cardiac dysfunction as well as the fact that transfu-
ion dependence is a feature of disease severity in MDS.31
owever, recent studies using the CMR  T2 technique have
hown that cardiac iron accumulation is quite variable but
nfrequent among patients with MDS.  Moreover, cardiac iron
n MDS  patients does not correlate with serum ferritin or hep-
tic iron, but shows correlation with the chelatable iron pool as
etermined by urinary iron excretion, a surrogate for LPI.32 It
emains to be determined whether LPI directly correlates with
yocardial iron in MDS.  Mechanisms leading to cardiac iron
eposition in particular patients with lower grades of MDS,
specially as it relates to hepcidin level, ineffective erythro-
oiesis, and elevated LPI, need further evaluation in larger
tudies.
Prospective studies correlating cardiac iron with cardiac
unction and survival as well as studies showing improvement
n cardiac function with chelation will be necessary before
igure 2 – Cardiovascular magnetic resonance T2* images showi
he same echo time (10.70 ms). (A) Dark signal indicating severe m
iver signal suggesting mild iron deposition.
mages courtesy of Dr S. Mavrogeni (Onassis Cardiac Surgery Cen 1 5;3  7(4):252–258 255
averting or reversing cardiac dysfunction can be established
as a primary goal of iron chelation in MDS.
Role  of  magnetic  resonance  imaging  in  the
evaluation  of  iron  overload
MRI  uses the magnetic properties of the human body to
provide pictures of any tissue (Figure 2). Hydrogen nuclei
are a principal constituent of body tissues in water and lipid
molecules and produce a dipole moment (magnetic ﬁeld) that
can interact with an external magnetic ﬁeld. MRI machines
generate a strong, homogenous magnetic ﬁeld by using a
large magnet, made by passing an electric ﬁeld through super-
conducting coils of wire. Hydrogen nuclei in the body, which
normally have randomly oriented spins, when exposed to the
magnetic ﬁeld, align in a direction parallel to the magnetic
ﬁeld. The MRI machine applies short electromagnetic pulses
at a speciﬁc radiofrequency (RF). The hydrogen nuclei absorb
the RF energy and precess away from equilibrium. When
the RF pulse is turned off, the precessing nuclei release the
absorbed energy and return to normal. The strength of the
signal varies, depending on the RF magnetic ﬁeld applied. The
examined tissue returns to normal in the longitudinal plane
over a characteristic interval called T1 relaxation time. In the
transverse plane, the return to normal occurs over a character-
istic interval called T2 relaxation time. Using MRI, tissue iron
is detected indirectly by the effects on relaxation times of fer-
ritin and hemosiderin iron interacting with hydrogen nuclei.
The presence of iron in the human body results in marked
alterations of tissue relaxation times.33 While T1 decreases
only moderately, T2 demonstrates a substantial decrease.34
Myocardial T2, a parameter measured by spin echo tech-
niques, has been shown in experimental animals to have an
inverse correlation with myocardial iron content.35 In a study
by our group that compared myocardial T2 with iron content
in heart biopsy, an agreement was found between myocardial
biopsy and the MRI results.36 Unfortunately, the MRI signal
is affected by multiple acquisition variables. Although T2 is
relatively independent of ﬁeld strength, there is an exception
ng the heart (H) and liver (L) from two different patients at
yocardial and liver siderosis. (B) Normal myocardial and
ter, Athens, Greece).
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in the case of iron overload. In these patients, there is the
linear dependence of T2 relaxivity (1/T2) on ﬁeld strength.37
Currently, CMR  using T2 is routinely used in many  coun-
tries to identify patients with myocardial iron overload and
guide chelation therapy tailored to the heart. Myocardial T2 is
calibrated to the myocardial iron concentration, and has been
shown to improve with intensive iron chelation in parallel
with the ejection fraction. Moreover, it is the major validated
non-invasive measure of myocardial iron overload and is supe-
rior to surrogates such as serum ferritin, liver iron, ventricular
ejection fraction and tissue Doppler parameters.38,39 Assess-
ment of cardiac iron by MRI  susceptometry has also been
validated, although availability of the technique is limited.40 In
most cases, chronic myocardial siderosis is both preventable
and reversible with modern chelation regimes.41 Progress
has also been made in the treatment of acute heart failure
and left ventricular systolic dysfunction.42 A substantial 71%
decrease in deaths has been observed in the UK thalassemia
cohort since the introduction of T2 CMR  and improved iron
chelation treatment.43 Other countries have also reported
important amelioration in management of cardiac iron using
T2 CMR.44,45 According to recent data, there is a substantial
prevalence of myocardial iron overload in a large interna-
tional sample of thalassemia major (TM) patients, who are
regularly transfused and taking iron chelation therapy. The
use of the threshold of T2 = 10 ms,  below which the risk of
cardiac complications rises signiﬁcantly, has been already
conﬁrmed and alternative explanations for heart failure apart
from myocardial iron overload seem unusual. The ﬁndings
from independent centers worldwide indicate that myocardial
T2 is a robust clinical tool with potential for further expansion
to guide chelation regimes which are tailored to prevent the
development of heart failure and prolong survival.46
Consequences  of  iron  deposition  in
myelodysplastic  syndromes
MRI  has already been used for the evaluation of myocardial
and liver iron overload in MDS.  In a study by our group, after
comparison of a population of patients with MDS  and TM
without evidence of heart failure using MRI, we  identiﬁed that
MDS  patients, who received a higher amount of blood transfu-
sions for longer time presented the same MRI  pattern in both
liver and heart as TM patients. On the contrary, MDS patients
who  received a lower amount of RBC transfusions for shorter
time had no evidence of myocardial iron. However, they still
had hepatic siderosis, because liver is the ﬁrst affected organ
in iron overload. Additionally, these patients had higher car-
diac indices indicative of high output state, due to chronic
anemia.47
Similar ﬁndings were also documented in other patient
groups with less frequent transfusions compared to TM,  but
similar to patients with thalassemia intermedia and sickle cell
disease.48 Recent reports have also assessed hepatic sidero-
sis without evidence of heart iron overload in these patients.
Additionally, ferritin reﬂects the total body iron and not the
iron in individual organs, as has been already described
in previous studies.49 These ﬁndings further emphasize the
necessity of MRI  in the evaluation of iron load, particularly 2 0 1 5;3  7(4):252–258
after recent publications proving the signiﬁcance of iron in
MDS prognosis and treatment.
Clinical  implications  of  magnetic  resonance
imaging  ﬁndings  in  the  treatment  of
myelodysplastic  syndromes
The iron overload assessment may have serious clinical impli-
cations in MDS.
In a ﬁve-year prospective registry that enrolled 600 lower
risk MDS  patients with transfusional iron overload, clinical
outcomes were compared between chelated and non-chelated
patients. At baseline, cardiovascular comorbidities were more
common in non-chelated patients. At 24 months, chelation
was associated with longer median overall survival (52.2
months vs. 104.4 months; p-value <0.0001) and a trend toward
longer leukemia-free survival and fewer cardiac events. No dif-
ference in safety was documented between groups.48 Finally,
a recent study showed that deferasirox was well tolerated
and effective in reducing S-ferritin and liver iron concentra-
tion (LIC) level in transfusional iron overload MDS  patients or
aplastic anemia.49 Therefore, iron chelation treatment should
be considered in transfused MDS patients when transfusion
related iron overload is documented.
Based on available data, the Expert Panel of the Italian
Society of Hematology agreed that iron chelation with defer-
oxamine should be considered as a therapy for MDS patients,
who have previously received more  than 50 RBC units and for
whom a life span longer than six months is expected.50 The
Expert Panel of the British Society of Hematology concluded
that iron chelation should be considered once a patient has
received 25 RBC units, but only in patients for whom long-
term transfusion therapy is likely, such as those with pure
sideroblastic anemia or the 5q-syndrome and deferoxamine
20–40 mg/kg should be administered by 12 h subcutaneous (sc)
infusion 5–7 days per week.51
The choice between deferoxamine and deferasirox is con-
troversial. Although deferoxamine is effective and relatively
safe (ocular and ear toxicity have been described), it requires
subcutaneous administration which is uncomfortable for
many patients. As an oral drug, deferasirox is easier for
patients, but its long-term effectiveness and safety have not
been deﬁned. Deferoxamine should be employed before allo-
geneic stem cell transplantation. Whether or not prevention
of severe iron overload by chelation will result in lower mor-
bidity and mortality in regularly transfused MDS  remains to be
proven. In a comparative study of deferasirox and deferiprone
in the treatment of iron overload in MDS patients, the inci-
dence of adverse effects (mostly gastrointestinal symptoms)
was similar after administration of both drugs. The symp-
toms of deferasirox toxicity were mild and mostly transient
and no drug-related myelosuppressive effect was observed in
contrast to deferiprone, where agranulocytosis occurred in 4%
of patients and the treatment had to be discontinued due to
side effects in 20% of patients. The results conﬁrmed the use-
fulness of deferasirox as an effective and safe iron chelator
in MDS patients and indication of deferiprone as an alterna-
tive treatment only in patients with mild or moderate iron
overload clearly not indicated for deferasirox.52
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onclusion
n conclusion, the MRI  imaging pattern of the liver and heart in
DS  shows that iron overload plays a crucial role in myocar-
ial and hepatic pathophysiology of these patients and may
lso inﬂuence MDS  survival. However, further studies are
eeded in order to identify the threshold for transfusions in
espect to provoking myocardial and hepatic iron deposition
nd the role of chelation in the long-term prognosis of MDS
atients.
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